The BLUEPRINT epigenome project aims to generate reference epigenomes and study them to advance knowledge of biological processes and mechanisms. Genomatix will provide data analysis and visualization interfaces as part of the $41 million European-funded consortium.
Genomatix introduces mygenomatix, a cloud-based NGS data analysis service providing fast turnaround times, access to full software content, and biological results. The service addresses the challenge of handling large datasets, offering security, ease of use, and affordability.
A multinational team identified a novel retinal disease gene, FAM161A, linked to RP28-associated recessive retinitis pigmentosa through ChIP-Seq analysis with Genomatix Genome Analyzer. The study provides new insights into visual perception and opens potential therapy avenues.
The new exome array includes 282,363 target regions representing 240,402 exonic regions, splice sites, proximal promoter regions and microRNAs for comprehensive analysis. This development fills the gap of missing medically important genes in current exome capturing systems.
The study found that 34% of polyadenylated transcripts mapped to non-annotated genomic regions, indicating a large number of novel gene candidates. Additionally, the researchers identified 94,241 splice junctions, with 4,096 novel variants, highlighting exon skipping as the most prevalent form of alternative splicing.
Researchers at NIA used Genomatix to identify two novel transcription factors, B-Myb and Maz, involved in maintaining undifferentiated stem cells or early differentiation. The study linked pluripotent stem cell-associated transcripts to regulatory gene networks.
LitInspector is a powerful literature and pathway mining system that offers quick and easy retrieval of pathways, genes, gene functions, and gene-gene interactions. The system utilizes cutting-edge text mining technology and leverages the largest gene synonym table available to provide comprehensive results.
A recent study integrates lipid metabolic profiling with gene expression analysis, demonstrating the synergistic power of combining metabolic profiling with proprietary microarray analysis methods. The results show that Por can be considered an enzyme critical for proper functioning of lipid mobilization in the mouse liver.
Researchers used Genomatix tools to identify novel cancer-associated genes in a colon cancer model. The study validated the findings using siRNA knock-down and RT-PCR, confirming the importance of these genes in cell proliferation.
Genomatix Software GmbH has won a $1.6 million BioChance grant to research RNAi mediated regulatory networks. The two-year project will expand its competence in this field, complemented by academic partners from LMU Munich and DKFZ Heidelberg.
Genomatix Software GmbH has appointed a distributor in China, Beijing ZGZ Science and Technology Development Co., Ltd., to expand its market presence. This partnership is significant for Genomatix, with over 1,800 researchers in China subscribed to its free services.
Researchers used Genomatix technology to identify new genes associated with renal disease, using comparative promoter analysis to predict cell junction proteins in the glomerular slit diaphragm. The approach effectively predicted a previously unrecognized molecule, which was experimentally verified.
Genomatix has developed a new version of ChipInspector specifically for analyzing exon arrays, which promises to enhance transcript separation and promoter identification. The updated tool is expected to be released in Q2 2006 and will be an integral part of Genomatix's complete microarray analysis pipeline.
A novel computational model predicts androgen receptor binding sites in the prostate cancer genome. Experimental verification confirms the accuracy of the model, providing new insights into prostate cancer biology.
The NIH has renewed its license with Genomatix, expanding the contract to include Microarray analysis Package ChipInspector. This move strengthens research capabilities in gene expression and regulation, facilitating high-level scientific results.